Lung Cancer Clinical Trials in Denver

Showing 61-80 of 569 trials

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

NCT04678648

RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.

Advanced Malignant Solid NeoplasmRAS MutationLung Cancer+3 more

RasCal Therapeutics, Inc.134 participantsStarted Mar 2021

Los Angeles, California, United States • Denver, Colorado, United States • Nashville, Tennessee, United States

Active Not RecruitingPhase 1< 1 mile

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

NCT05571839

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Cutaneous MelanomaNon-small Cell Lung CancerColorectal Neoplasms+2 more

Seagen, a wholly owned subsidiary of Pfizer41 participantsStarted Jan 2023

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +33 more locations

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Lung Cancer Trials in Other Cities

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed

Empathic Communication Skills (ECS) Training

Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer

Other Conditions in Denver